BCM
AGIO icon

Bayesian Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Bayesian Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,800
Closed -$241K – 758
2023
Q4 		$241K Buy
+10,800
New +$242K 0.03% 557
2023
Q2 		– Sell
-10,802
Closed -$248K – 764
2023
Q1 		$248K Buy
+10,802
New +$287K 0.03% 558

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bayesian Capital Management's AGIO Position: Q1 2024 in Review

Bayesian Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2024, closing a stake of 10,800 shares — an estimated $241K sold.

Bayesian Capital Management first reported a position in AGIO in Q1 2023 and held it in 2 quarters. The position peaked at $248K in Q1 2023. 186 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.

  • Bayesian Capital Management reported no remaining Agios Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,800 Agios Pharmaceuticals shares in Q1 2024, an estimated $241K.
  • Bayesian Capital Management first reported a position in Agios Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Bayesian Capital Management's Agios Pharmaceuticals position peaked at $248K in Q1 2023.
  • 186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.